BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38701952)

  • 1. Using electronic health records to evaluate the adherence to cervical cancer prevention guidelines: A cross-sectional study.
    Mooses K; Šavrova A; Pajusalu M; Oja M; Tamm S; Haug M; Padrik L; Laanpere M; Uusküla A; Kolde R
    Prev Med; 2024 Jun; 183():107982. PubMed ID: 38701952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unindicated cervical cancer screening in adolescent females within a large healthcare system in the United States.
    Hosier H; Sheth SS; Oliveira CR; Perley LE; Vash-Margita A
    Am J Obstet Gynecol; 2021 Dec; 225(6):649.e1-649.e9. PubMed ID: 34256029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of number of human papillomavirus vaccine doses on guideline adherent cervical cytology screening among 19-26year old females.
    Hirth JM; Lin YL; Kuo YF; Berenson AB
    Prev Med; 2016 Jul; 88():134-9. PubMed ID: 27085993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Papillomavirus Testing by Veterans Administration Women's Health Providers: Are They Adhering to Guidelines?
    Hallett LD; Gerber MR
    J Womens Health (Larchmt); 2018 Feb; 27(2):179-182. PubMed ID: 28885082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus vaccination and subsequent cervical cancer screening in a large integrated healthcare system.
    Chao C; Silverberg MJ; Becerra TA; Corley DA; Jensen CD; Chen Q; Quinn VP
    Am J Obstet Gynecol; 2017 Feb; 216(2):151.e1-151.e9. PubMed ID: 27746152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated With Guideline-concordant and Excessive Cervical Cancer Screening: A Mixed Methods Study.
    Perkins RB; Fuzzell L; Lake P; Brownstein NC; Fontenot HB; Michel A; Whitmer A; Vadaparampil ST
    Womens Health Issues; 2024; 34(3):257-267. PubMed ID: 38383228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
    Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
    Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cervical Screening and Colposcopy Management of Women Age 24 and Under.
    Buick C; Jembere N; Wang L; Kupets R
    J Obstet Gynaecol Can; 2020 Dec; 42(12):1518-1524. PubMed ID: 32988802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Cervical Cancer Screening Among Infrequently Screened Women Completing Human Papillomavirus Self-Collection: My Body My Test-1.
    Lea CS; Perez-Heydrich C; Des Marais AC; Richman AR; Barclay L; Brewer NT; Smith JS
    J Womens Health (Larchmt); 2019 Aug; 28(8):1094-1104. PubMed ID: 30874477
    [No Abstract]   [Full Text] [Related]  

  • 10. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
    Cox JT;
    Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in cervical cancer screening and follow-up for black and white women in the United States.
    Ford S; Tarraf W; Williams KP; Roman LA; Leach R
    Gynecol Oncol; 2021 Feb; 160(2):369-374. PubMed ID: 33323276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated Positive Cervical HPV Testing and Absent or Minor Cytology Abnormality at Pap Smear. What is the Next Step?
    Caeiro V; Nunes S; Esteves B; Moutinho-Fonseca J
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1907-1912. PubMed ID: 34181350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus and Papanicolaou tests to screen for cervical cancer.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Johansson B; Forslund O; Hansson BG; Rylander E; Dillner J
    N Engl J Med; 2007 Oct; 357(16):1589-97. PubMed ID: 17942872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.
    Gage JC; Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Behrens C; Sharma A; Zhao FH; Cuzick J; Yang ZH; Kinney WK
    Cancer Cytopathol; 2014 Nov; 122(11):842-50. PubMed ID: 25045058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chatbot-interfaced and cognitive-affective barrier-driven messages to improve colposcopy adherence after abnormal Pap test results in underserved urban women: A feasibility pilot study.
    Wen KY; Dayaratna S; Slamon R; Granda-Cameron C; Tagai EK; Kohler RE; Hudson SV; Miller SM
    Transl Behav Med; 2024 Jan; 14(1):1-12. PubMed ID: 38014626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical cancer screening and subsequent procedures in women under the age of 25 years between 2007 and 2013 in France: a nationwide French healthcare database study.
    Maura G; Chaignot C; Weill A; Alla F; Heard I
    Eur J Cancer Prev; 2018 Sep; 27(5):479-485. PubMed ID: 28368950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.